[High methotrexate doses in the treatment program for acute lymphoblastic leukemia and lymphosarcoma in children].
Tolerability and efficacy of high-dose methotrexate was studied in 70 pediatric patients with lymphoblastic tumors (acute lymphoblastic leukemia and non-Hodgkin's lymphoma). Methotrexate was given by 24-hour infusion of 500-1000 mg/m2 (total dose-700-3000 mg) after remission had been achieved. An antidote--calcium folinate--was administered 24 hours postinfusion. Major adverse side-effects involved were stomatitis, hepatotoxicity and fever. Survival in the study group was higher than in controls.
Makhonova
L A
LA
Maiakova
S A
SA
Kiselev
A V
AV
Gordina
G A
GA
Balakirev
S A
SA
Gavrilova
I E
IE
Moiseenko
E I
EI
Morozova
O V
OV
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007223:Infant; D002955:Leucovorin / Q000008:administration & dosage; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000188:drug therapy*; D011379:Prognosis; D012074:Remission Induction; D013997:Time Factors
D002955:Leucovorin; D008727:Methotrexate
Povyshennye dozy metotreksata v programme lecheniia ostrogo limfoblastnogo leĭkoza i limfosarkomy u deteĭ.